title: Effects of changes in basal/total daily insulin ratio in type 2 diabetes patients on intensive insulin therapy including insulin glargine (JUN-LAN Study 6).
abstract: Intensive insulin therapy composed of bolus and basal insulin has been believed as the most powerful recipe for glycemic control of both type 1 and type 2 diabetes. In this study, we investigated the effects of changes in basal/total daily insulin ratio (B/TD ratio) in type 2 diabetes patients on intensive insulin therapy including insulin glargine. The B/TD ratio used in our Japanese patients was about 0.35, and the ratio was increased up to about 0.46+/-0.12 without change of total insulin daily dose. After 24-week-treatment, mean glycated albumin of the patients whose B/TD ratio was increased was significantly lower than those of the patients whose B/TD ratio was not changed. Our results suggest that adequate supplementation of basal insulin may be important for maximum effect of bolus insulin even in Japanese who have serious defect in postprandial rapid insulin secretion.
authors.affiliation: Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113-8421, Japan.
authors.forename: Motoyuki
authors.initials: M
authors.lastname: Tamaki
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Shimizu
authors.forename: Akio
authors.initials: A
authors.lastname: Kanazawa
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Fujitani
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Watada
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Kawamori
authors.forename: Takahisa
authors.initials: T
authors.lastname: Hirose
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D017127:Glycation End Products, Advanced; D006031:Glycosylation; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000069036:Insulin Glargine; D007336:Insulin, Isophane / Q000627:therapeutic use; D049528:Insulin, Long-Acting; D012709:Serum Albumin / Q000378:metabolism; D000093423:Glycated Serum Albumin
chemical_list: D017127:Glycation End Products, Advanced; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D012709:Serum Albumin; D000069036:Insulin Glargine; D007336:Insulin, Isophane; D000093423:Glycated Serum Albumin